HUAWEI DESIGN
833427
Shanghai Kaytune Industrial
301001
Ji Yao Holding Group
300108
Zhengzhou Tiamaes Technology
300807
Jiangsu Canlon Building Materials
300715
CN Stock MarketDetailed Quotes
603739 Qingdao Vland Biotech INC.
- 11.49
- -0.31-2.63%
Noon Break Jan 8 11:29 CST
2.91BMarket Cap43.85P/E (TTM)
11.87High11.46Low18.15KlotVolume11.71Open11.80Pre Close21.18MTurnover0.72%Turnover Ratio36.02P/E (Static)253.03MShares22.2552wk High1.68P/B2.91BFloat Cap7.6052wk Low12.98Limit Up253.03MShs Float29.90Historical High10.62Limit Down3.48%Amplitude7.60Historical Low0.10Dividend TTM11.67Avg Price11.56KlotAsk0.87%Div YieldTTM100Lot Size6.35KlotBid
Qingdao Vland Biotech INC. News
Qingdao Vland Biotech INC. (603739.SH): plans to reduce the capital of its subsidiary Vland Pet by 60 million yuan.
On December 27, GELONGHUI reported that Qingdao Vland Biotech INC. (603739.SH) announced plans to reduce the capital of its wholly-owned subsidiary Vland Pet to 60 million yuan. After the completion of this capital reduction, Vland Pet's registered capital will decrease from 70 million yuan to 10 million yuan.
Qingdao Vland Biotech Gets China Nod for Bird Flu Vaccine, Treatment
Express News | Qingdao Vland Biotech INC.: Received a new veterinary drug registration certificate.
Express News | Summary of Shareholding adjustments on December 17.
Express News | Qingdao Vland Biotech INC.: The Director and Chief Financial Officer intend to reduce their shareholding.
Blue Biotech: Report for the third quarter of 2024 from Qingdao Weilan Biology Co., Ltd.
Qingdao Weilan Biology Co., Ltd. Report for the Third Quarter of 2024
Announcement of the main operating data of Qingdao Weilan Biology Co., Ltd. for the third quarter of 2024
Qingdao Vland Biotech Inc. (603739.SH): The net income in the first three quarters is approximately 40.85 million yuan, a decrease of 26.17% year-on-year.
Galaxy Securities reported on October 28 that qingdao vland biotech inc. (603739.SH) announced that the revenue in the first three quarters of 2024 was approximately 0.946 billion yuan, an increase of 7.5% year-on-year; the net income attributable to the shareholders of the listed company was approximately 40.85 million yuan, a decrease of 26.17% year-on-year; and the basic earnings per share was 0.16 yuan.
Qingdao Vland Biotech Inc. (603739.SH) released its performance for the first three quarters, with a net income of 40.85 million yuan, a year-on-year decrease of 26.17%.
Qingdao Vland Biotech Inc. (603739.SH) disclosed its third quarter report for 2024, with the company achieving revenue of 9....
guilin seamild foods (002956.SZ): Joint experiments and applied research with qingdao vland biotech inc. on the development of oats enzyme hydrolysis technology and oats milk series products.
Guilin Seamild Foods (002956.SZ) stated on the investor interaction platform on October 23 that the company has conducted joint experiments and applied research with qingdao vland biotech inc. on oats enzyme technology and oat milk series products, and will expand into more areas in the future.
Vland Biotech to Provide 50 Million Yuan Guarantees to Two Subsidiaries
Qingdao Vland Biotech Inc. (603739.SH): Intends to terminate the construction of the research and industrialization project of microbial ecological preparations.
Qingdao Vland Biotech Inc. (603739.SH) announced on September 19th that, based on actual business conditions and future business plans, after careful analysis and friendly negotiations, Qingdao Vland Biotech Group and ADMSingapore signed the 'Agreement on the Termination of the Restated Shareholder Agreement' on September 19th, 2024. Both parties plan to terminate the construction of the microecological preparation research and industrialization project, dissolve the joint venture company, and proceed with liquidation. As of the date of this announcement, the civil construction part of the microecological preparation research and industrialization project has not yet started construction and is still in the initial planning and construction stage. The construction of this project and the joint venture company will be terminated.
qingdao vland biotech inc. (603739.SH) terminates the implementation of the 2021 stock options incentive plan.
Qingdao Vland Biotech Inc. (603739.SH) announced that, given the internal and external environment the company is facing, the company has formulated
Qingdao Vland Biotech Inc. (603739): Enzyme preparation sector maintains growth, multiple business layouts synergize for greater impact.
Key point 24H1 The company achieved revenue of 0.609 billion yuan, a year-on-year increase of +12.00%, and net income attributable to shareholders of 0.029 billion yuan, a year-on-year decrease of -6.73%; 24Q2 achieved revenue of 0.322 billion yuan, a year-on-year +
Qingdao Vland Biotech Inc. (603739): Technologically-driven development, basic completion of production capacity layout.
Event: The company released the 2024 interim report. The first half of the year revenue was 0.609 billion yuan, up 12% year-on-year, and the net income attributable to the mother was 0.029 billion yuan, down 6.73% year-on-year; of which Q2 revenue was 0.322 billion yuan, up 3.55% year-on-year.
2024 Semi-Annual Report of Qingdao Weilan Biology Co., Ltd.
Summary of the 2024 semi-annual report of Qingdao Weilan Biology Co., Ltd.
Express News | Qingdao Vland Biotech Inc.: net income in the first half of the year was 29.35 million yuan, a year-on-year decrease of 6.73%.
Express News | qingdao vland biotech inc.: Revenue increased by 12% in the first half of 2024.
